NASDAQ : APRE
Aprea Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.4846 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 6.10M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 6.10M |
| Enterprise Value | -35.13M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 12.59M |
| Shares Outstanding | 12.59M |
| Shares Change (YoY) | +243.85% |
| Shares Change (QoQ) | +264.19% |
| Owned by Insiders (%) | 8.98% |
| Owned by Institutions (%) | 11.57% |
| Float | 7.90M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,176.79 |
| Forward PS | n/a |
| PB Ratio | 0.16 |
| P/TBV Ratio | 0.16 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 13.55 |
| Quick Ratio | 13.33 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -46.15% |
| Return on Assets (ROA) | -27.73% |
| Return on Invested Capital (ROIC) | -30.99% |
| Return on Capital Employed (ROCE) | -33.73% |
| Weighted Average Cost of Capital (WACC) | 13.55% |
| Revenue Per Employee | $648 |
| Profits Per Employee | -$1.54M |
| Employee Count | 8 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.69 |
| 52-Week Price Change | -66.58% |
| 50-Day Moving Average | 0.70 |
| 200-Day Moving Average | 0.75 |
| Relative Strength Index (RSI) | 36.28 |
| Average Volume (20 Days) | 184,712 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 621,151 |
| Short Previous Month | 508,841 |
| Short % of Shares Out | 4.93% |
| Short % of Float | 7.86% |
| Short Ratio (days to cover) | 2.56 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 5,185 |
| Gross Profit | -6.72M |
| Operating Income | -13.22M |
| Pretax Income | -12.31M |
| Net Income | -12.31M |
| EBITDA | -13.20M |
| EBIT | -13.22M |
| Loss Per Share | -$0.60 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 41.23M |
| Total Debt | n/a |
| Net Cash | 41.23M |
| Net Cash Per Share | $3.27 |
| Equity (Book Value) | 39.20M |
| Book Value Per Share | 3.10 |
| Working Capital | 38.82M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -12.17M |
| Capital Expenditures | -15,400 |
| Depreciation & Amortization | 22,032 |
| Net Borrowing | n/a |
| Free Cash Flow | -12.18M |
| FCF Per Share | -$0.97 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -255,025.52% |
| Pretax Margin | -237,362.80% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -243.85% |
| Shareholder Yield | n/a |
| Earnings Yield | -123.19% |
| FCF Yield | -199.67% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $3.30 |
| Price Target Difference | 580.97% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Feb 13, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -9.6 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |